All In Biotech

Drug Trial Radar · NCT00556374

Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy

A Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Phase 3 Study to Determine the Treatment Effect of Denosumab in Subjects With Non-Metastatic Breast Cancer Receiving Aromatase Inhibitor Therapy.

Last checked: Nov 19, 2026Latest source record: Jul 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 3,420 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,420

Actual

Start

Dec 18, 2006

Primary completion

Oct 7, 2014

Study completion Jul 26, 2022

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
Collaborators
Austrian Breast & Colorectal Cancer Study Group
First posted
Nov 12, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Supportive care
Who can join
Female only, from 45 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether denosumab compared to placebo, will reduce the rate of first clinical fracture in women with non-metastatic breast cancer receiving (non-steroidal) aromatase inhibitor therapy.

Conditions

  • Breast Cancer

Interventions

  • PlaceboDrug

  • DenosumabBiological

    Administered as a subcutaneous injection

  • Non-steroidal aromatase inhibitor therapyDrug

    An approved non-steroidal aromatase inhibitor therapy (eg, anastrazole) in the adjuvant setting

  • Zoledronic AcidDrug

    5 mg zoledronic acid administered at a constant infusion rate

  • Standard of CareOther

    Standard of care (SoC) as recommended by the treating physician, depending on individual factors such as bone density, lifestyle recommendations by the Investigator such as diet, physical activities and sun exposure, as well as local treatment standards.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to First Clinical FractureTime frame: From randomization until the primary analysis cut-off date of 26 March 2014; maximum time on main study at the cut-off was 87 months

Locations

46 sites in 2 countries. Site status is shown where the registry gives one.

  • Research Site

    Baden, Austria

  • Research Site

    Braunau am Inn, Austria

  • Research Site

    Dornbirn, Austria

  • Research Site

    Feldkirch, Austria

  • Research Site

    Gmunden, Austria

  • Research Site

    Graz, Austria

  • Research Site

    Graz, Austria

  • Research Site

    Guessing, Austria

  • Research Site

    Hall in Tirol, Austria

  • Research Site

    Innsbruck, Austria

  • Research Site

    Klagenfurt, Austria

  • Research Site

    Krems, Austria

  • Research Site

    Kufstein, Austria

  • Research Site

    Leoben, Austria

  • Research Site

    Lienz, Austria

  • Research Site

    Linz, Austria

  • Research Site

    Linz, Austria

  • Research Site

    Oberpullendorf, Austria

  • Research Site

    Ried, Austria

  • Research Site

    Rottenmann, Austria

  • Research Site

    Salzburg, Austria

  • Research Site

    Sankt Pölten, Austria

  • Research Site

    Sankt Veit an der Glan, Austria

  • Research Site

    Schaerding, Austria

  • Research Site

    Steyr, Austria

  • Research Site

    Vienna, Austria

  • Research Site

    Vienna, Austria

  • Research Site

    Vienna, Austria

  • Research Site

    Vienna, Austria

  • Research Site

    Vienna, Austria

  • Research Site

    Vienna, Austria

  • Research Site

    Vienna, Austria

  • Research Site

    Vienna, Austria

  • Research Site

    Vienna, Austria

  • Research Site

    Villach, Austria

  • Research Site

    Villach, Austria

  • Research Site

    Vöcklabruck, Austria

  • Research Site

    Weiz, Austria

  • Research Site

    Wels, Austria

  • Research Site

    Wiener Neustadt, Austria

Showing 40 of 46 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.